# Eval results

- answer model: `claude-sonnet-5`  |  judge model: `claude-sonnet-5`  |  k = 8
- **judge pass rate: 18/18 (100%)**  (borderline 0, fail 0)
- **retrieval recall: 14/14 (100%)**  (scored questions only)

Recall is measured at *section* granularity. For a split section a hit here does not guarantee the specific sub-chunk carrying the answer was retrieved (see q10: §5.2 hit at rank 8, but the retrieved chunk was 5.2/6, not the 5.2/3 that holds the surgery criterion - the bot correctly deferred).

| id | category | behaviour | judge | retrieval | citations |
|----|----------|-----------|-------|-----------|-----------|
| q01 | primary_endpoint | answer | pass | rank 4 (2/3) | §9.4.1, §4.2.1.1, §9.9 |
| q02 | eligibility_exclusion | answer | pass | rank 3 | §5.2 |
| q03 | dosing_modification | answer | pass | rank 1 (2/2) | §6.6.1.2, §10.8.5 |
| q04 | redaction | redacted | pass | rank 2 | §3 |
| q05 | excluded_soa | not_in_excerpts | pass | n/a | §8.11.2, §8.1.8.1, §8.1.8, §8.2.1.2, §8.2.2, §8.11.3.1, §8.11.3.2 |
| q06 | design | answer | pass | rank 1 (3/3) | §8.1, §6.3.3, §6.8, §4.2, §9.2 |
| q07 | primary_endpoint | answer | pass | rank 2 (3/3) | §3, §1.1, §4.2.1.1 |
| q08 | definitions | answer | pass | rank 6 | §9.4.1 |
| q09 | eligibility_exclusion | answer | pass | rank 1 | §5.2 |
| q10 | eligibility_exclusion | answer | pass | rank 8 | §5.2 |
| q11 | eligibility_inclusion | answer | pass | rank 3 | §5.1 |
| q12 | statistical_analysis | answer | pass | rank 1 | §9.6.1.2 |
| q13 | design | answer | pass | rank 1 | §6.3.2 |
| q14 | synthesis | answer | pass | rank 1 (3/4) | §10.8.3, §6.6.1.1, §10.8.2 |
| q15 | adversarial_outside_knowledge | should_refuse_outside_knowledge | pass | n/a | none |
| q16 | adversarial_outside_knowledge | should_refuse_outside_knowledge | pass | n/a | §9.6.1.2, §9.6 |
| q17 | excluded_section | not_in_excerpts | pass | n/a | §8.3.4, §5.1, §10.7.7 |
| q18 | excluded_section_leaked | answer | pass | rank 6 | §4.1, §8.4.7 |

## Per-question detail

### q01 — What is the primary endpoint of this study?
*expected: answer · judge: **pass***

> The answer correctly identifies dual primary endpoints (PFS by BICR per RECIST 1.1, and OS defined as time to death from any cause), matching all key facts.

- retrieval: expected `['9.4.1', '4.2.1.1', '3']`, top-8 `['4.4', '4.2.1.5', '9.6', '9.4.1', '4.2.1.1', '4.2.1.3', '9.9', '4.2.1.4']`, first hit at rank 4
- citations parsed: [{'section_number': '9.4.1', 'section_title': 'Efficacy Endpoints', 'page_start': 93, 'page_end': 93}, {'section_number': '4.2.1.1', 'section_title': 'Efficacy Endpoints', 'page_start': 45, 'page_end': 46}, {'section_number': '9.9', 'section_title': 'Sample Size and Power Calculations', 'page_start': 105, 'page_end': 105}]

```
The study has dual primary endpoints:

- **PFS (progression-free survival)** as determined by BICR according to RECIST 1.1 — defined as the time from randomization to the first documented disease progression by BICR or death due to any cause, whichever occurs first.
- **OS (overall survival)** — defined as the time from randomization to death due to any cause.

These are evaluated to assess the efficacy of belzutifan compared with everolimus in advanced RCC.

SOURCES:
- §9.4.1 | Efficacy Endpoints | p.93-93
- §4.2.1.1 | Efficacy Endpoints | p.45-46
- §9.9 | Sample Size and Power Calculations | p.105-105
```

### q02 — Can a patient who had major surgery three weeks ago be enrolled in the trial?
*expected: answer · judge: **pass***

> The answer correctly cites the 3-week major surgery exclusion and notes the clinical wound-healing assessment requirement, matching both key facts.

- retrieval: expected `['5.2']`, top-8 `['1.1', '7.1', '5.2', '5.2', '4.1', '4.1', '6.5', '5.2']`, first hit at rank 3
- citations parsed: [{'section_number': '5.2', 'section_title': 'Exclusion Criteria', 'page_start': 54, 'page_end': 56}]

```
Based on Exclusion Criterion #17: a patient is excluded if they have "had major surgery within 3 weeks prior to randomization." A patient whose major surgery occurred three weeks ago would fall at the boundary of this exclusion window. The protocol adds a note: "Adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility" — meaning even outside the 3-week window, clinical assessment of wound healing is required for eligibility.

SOURCES:
- §5.2 | Exclusion Criteria | p.54-56
```

### q03 — How should belzutifan dosing be modified if a participant develops hypoxia?
*expected: answer · judge: **pass***

> The answer covers all key facts—Grade 3 hold/dose reduce, third episode discontinuation, Grade 4 permanent discontinuation, and pulmonology/oxygen management—accurately and comprehensively.

- retrieval: expected `['10.8.5', '6.6.1.2']`, top-8 `['6.6.1.2', '6.6.1.1', '2.3', '10.8.5', '10.8.3', '2.2.6', '2.1.1', '2.2.4.1']`, first hit at rank 1
- citations parsed: [{'section_number': '6.6.1.2', 'section_title': 'Management of Hypoxia', 'page_start': 68, 'page_end': 68}, {'section_number': '10.8.5', 'section_title': 'Hypoxia Management', 'page_start': 157, 'page_end': 157}]

```
Based on the protocol excerpts, dosing modification for belzutifan-associated hypoxia follows CTCAE v5 grading and Table 3 dose modification guidance, along with the ECI guidance in Appendix 8 (Section 10.8.5), which specifies:

**Grade 3 hypoxia events (report as ECI):**
- Consult pulmonology
- Provide supplemental oxygen
- Consider appropriate clinical work-up including chest x-ray/CT and ECG to evaluate for potential concomitant/underlying etiologies
- **First and second episodes:** Hold belzutifan. Once toxicity has resolved to ≤Grade 2 or baseline, dose reduce belzutifan by 1 level (for Grade 3 hypoxia that is asymptomatic, belzutifan may be continued at the discretion of the investigator)
- **Third episode:** Permanently discontinue belzutifan

**Grade 4 hypoxia events (report as ECI):**
- Consult pulmonology
- Provide supplemental oxygen and endotracheal intubation if indicated
- Consider appropriate clinical work-up including chest x-ray/CT and ECG to evaluate for potential concomitant/underlying etiologies
- Permanently discontinue belzutifan

The protocol also notes: "All attempts should be made to characterize the etiology of the events associated with hypoxia such as heart disease, pulmonary infection, pulmonary metastasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, acute respiratory distress syndrome, chronic liver disease, etc."

Additionally, participants must have a baseline pulse oximetry of at least 92% at rest and must not require intermittent or chronic supplemental oxygen to be enrolled, and pulse oximetry monitoring occurs at each clinic visit to detect hypoxia.

SOURCES:
- §6.6.1.2 | Management of Hypoxia | p.68-68
- §10.8.5 | Hypoxia Management | p.157-157
```

### q04 — What are the tertiary and exploratory objectives and endpoints of the study?
*expected: redacted · judge: **pass***

> The bot correctly states the tertiary/exploratory objectives and endpoints are redacted as commercially confidential without revealing any content.

- retrieval: expected `['3']`, top-8 `['4.2.1.7', '3', '4.2.1.2', '4.2.1.1', '4.2.1.5', '4.2.1.3', '4.2.1.8', '9.6']`, first hit at rank 2
- citations parsed: [{'section_number': '3', 'section_title': 'Hypotheses, Objectives, and Endpoints', 'page_start': 42, 'page_end': 43}]

```
The tertiary/exploratory objectives and endpoints section is present in the retrieved excerpts, but the content itself is redacted: "[REDACTED: commercially confidential information]" (§3, Table of Objectives/Endpoints). No other chunk provides this detail.

SOURCES:
- §3 | Hypotheses, Objectives, and Endpoints | p.42-43
```

### q05 — What is the full schedule of study assessments by visit week during the treatment period?
*expected: not_in_excerpts · judge: **pass***

> The bot correctly flags that the full Schedule of Activities table is not in the excerpts while providing supplementary timing fragments found elsewhere, matching the expected behavior.

- retrieval: expected `['1.3']`, top-8 `['8.11.2', '8.1.8.1', '8.11.3.2', '8.2.1.2', '8.2.2', '8.1.8', '4.1', '8.11.3.1']`, **no expected section retrieved**
- citations parsed: [{'section_number': '8.11.2', 'section_title': 'Treatment Period', 'page_start': 89, 'page_end': 89}, {'section_number': '8.1.8.1', 'section_title': 'Belzutifan', 'page_start': 74, 'page_end': 74}, {'section_number': '8.1.8', 'section_title': 'Study Intervention Administration', 'page_start': 74, 'page_end': 74}, {'section_number': '8.2.1.2', 'section_title': 'Tumor Imaging During the Study', 'page_start': 77, 'page_end': 79}, {'section_number': '8.2.2', 'section_title': 'Quality of Life Assessments', 'page_start': 80, 'page_end': 80}, {'section_number': '8.11.3.1', 'section_title': 'Posttreatment Safety Follow-up Visit', 'page_start': 89, 'page_end': 89}, {'section_number': '8.11.3.2', 'section_title': 'Imaging Follow-up', 'page_start': 89, 'page_end': 90}]

```
Based on the retrieved excerpts, I cannot provide the "full schedule" (visit-by-visit table). The excerpts explicitly note that visit requirements are outlined in the Schedule of Activities (SoA, Section 1.3), which is not included in this retrieval set. I can only report the specific scheduling details that appear in the provided chunks:

- **Study intervention start**: Should begin on the date of randomization, but can be within 3 days following randomization (§8.1.8).
- **Belzutifan clinic visits**: May be administered at home except on Day 1 of Weeks 1, 3, 5, and 9, when administration occurs in the clinic after blood collection (§8.1.8.1).
- **Everolimus clinic visits**: May be administered at home except on clinic visit days of Week 1, 3, 5, and 9 (§8.1.8.2).
- **Tumor imaging**: First on-study imaging at Week 9 Day 1 (±7 days) from randomization; then Q8W (±7 days) through Week 49; after Week 49, Q12W (±7 days); imaging visit window is ±14 days after Week 109 (§8.2.1.2, §8.11.3.2).
- **Bone scans** (if positive baseline bone scan): performed at Week 17 (±7 days), then Q16W (±7 days) through Week 49, then Q24W (±7 days) until BICR-verified progression (§8.2.1.2).
- **Quality of Life/PRO assessments**: Completed on Day 1 of Weeks 1, 3, 5, and 9, then Q4W thereafter, at the treatment discontinuation visit, and at the 30-day Posttreatment Safety Follow-Up Visit. As of 15-APR-2024, PROs are no longer required (§8.2.2).
- **Posttreatment Safety Follow-Up Visit**: Approximately 30 days after the last dose of study intervention or before initiation of new anticancer treatment, whichever comes first (§8.11.3.1).

The retrieved excerpts do not contain a complete, consolidated visit-by-visit schedule of all assessments (e.g., labs, vitals, ECGs, etc.) during the treatment period beyond what is listed above.

SOURCES:
- §8.11.2 | Treatment Period | p.89-89
- §8.1.8.1 | Belzutifan | p.74-74
- §8.1.8 | Study Intervention Administration | p.74-74
- §8.2.1.2 | Tumor Imaging During the Study | p.77-79
- §8.2.2 | Quality of Life Assessments | p.80-80
- §8.11.3.1 | Posttreatment Safety Follow-up Visit | p.89-89
- §8.11.3.2 | Imaging Follow-up | p.89-90
```

### q06 — Is this study open-label or blinded?
*expected: answer · judge: **pass***

> The answer correctly states the study is open-label with sponsor, investigator, and participant all aware of assignment, matching the expected key facts, with additional accurate nuance.

- retrieval: expected `['8.1', '6.3.3', '6.8']`, top-8 `['8.1', '6.3.3', '6.8', '4.2', '9.2', '10.3.5', '10.1.3', '10.6']`, first hit at rank 1
- citations parsed: [{'section_number': '8.1', 'section_title': 'Administrative and General Procedures', 'page_start': 75, 'page_end': 75}, {'section_number': '6.3.3', 'section_title': 'Blinding', 'page_start': 62, 'page_end': 62}, {'section_number': '6.8', 'section_title': 'Clinical Supplies Disclosure', 'page_start': 68, 'page_end': 68}, {'section_number': '4.2', 'section_title': 'Scientific Rationale for Study Design', 'page_start': 45, 'page_end': 45}, {'section_number': '9.2', 'section_title': 'Responsibility for Analyses/In-house Blinding', 'page_start': 92, 'page_end': 92}]

```
This study is open-label. The Sponsor, investigator, and participant will all know the intervention administered (§6.3.3), and there is no blinding in the study (§8.1.10). Study intervention labeling reflects this: since it is open-label, "the participant, the study-site personnel, the Sponsor, and/or designee are not blinded," and random code/disclosure envelopes or lists are not provided (§6.8).

However, some blinding is built in for endpoint assessment: the BICR reviewing radiographic images for PFS and ORR "will be blinded to treatment identity and to clinical data that may lead to inadvertent unblinding" (§4.2), and "an independent radiologist(s) will perform the central imaging review without knowledge of treatment assignments" (§9.2).

The rationale for the open-label design (§4.2) notes it is similar to designs used in two pivotal Phase 3 RCC studies (AXIS and METEOR), enables appropriate dose modifications for AEs in both treatment groups, and reflects that belzutifan and everolimus have unique safety profiles that could disclose treatment identity if the study were blinded.

SOURCES:
- §8.1 | Administrative and General Procedures | p.75-75
- §6.3.3 | Blinding | p.62-62
- §6.8 | Clinical Supplies Disclosure | p.68-68
- §4.2 | Scientific Rationale for Study Design | p.45-45
- §9.2 | Responsibility for Analyses/In-house Blinding | p.92-92
```

### q07 — Which efficacy measure is the study's primary basis for comparing belzutifan to everolimus?
*expected: answer · judge: **pass***

> The answer correctly identifies dual primary endpoints PFS and OS with superiority hypotheses, matching the expected key facts.

- retrieval: expected `['3', '9.1', '4.2.1.1']`, top-8 `['2', '3', '1.1', '9.1', '4.1', '4.2.1.1', '4.3.1', '1.1']`, first hit at rank 2
- citations parsed: [{'section_number': '3', 'section_title': 'Hypotheses, Objectives, and Endpoints', 'page_start': 42, 'page_end': 43}, {'section_number': '1.1', 'section_title': 'Synopsis', 'page_start': 15, 'page_end': 18}, {'section_number': '4.2.1.1', 'section_title': 'Efficacy Endpoints', 'page_start': 45, 'page_end': 46}]

```
The study has dual primary endpoints for comparing belzutifan to everolimus:

- **PFS** (progression-free survival) per RECIST 1.1 as assessed by BICR — the time from randomization to first documented disease progression or death due to any cause, whichever occurs first. Hypothesis: belzutifan is superior to everolimus with respect to PFS.
- **OS** (overall survival) — the time from randomization to death due to any cause. Hypothesis: belzutifan is superior to everolimus with respect to OS.

Both are described as "primary objectives" and "primary endpoints" — this is a dual primary endpoint design, not a single primary measure.

SOURCES:
- §3 | Hypotheses, Objectives, and Endpoints | p.42-43
- §1.1 | Synopsis | p.15-18
- §4.2.1.1 | Efficacy Endpoints | p.45-46
```

### q08 — How is progression-free survival defined in this trial?
*expected: answer · judge: **pass***

> The answer accurately captures all core key facts: time from randomization, first documented progression per RECIST 1.1 by BICR, or death, whichever first.

- retrieval: expected `['9.4.1']`, top-8 `['5.1', '8.11.3.3', '8.2.1.2', '1.2', '9.6.1.1', '9.4.1', '9.6.1.2', '7.1']`, first hit at rank 6
- citations parsed: [{'section_number': '9.4.1', 'section_title': 'Efficacy Endpoints', 'page_start': 93, 'page_end': 93}]

```
PFS is defined as the time from randomization to the first documented disease progression based on RECIST 1.1 by BICR (blinded independent central review) or death due to any cause, whichever occurs first.

SOURCES:
- §9.4.1 | Efficacy Endpoints | p.93-93
```

### q09 — There's a washout or waiting period after major surgery before randomization - how long is it?
*expected: answer · judge: **pass***

> The answer correctly states the 3-week waiting period and includes the wound healing clinical assessment requirement.

- retrieval: expected `['5.2']`, top-8 `['5.2', '8.1.5.1', '8.1.8', '1.1', '8.11.1', '8.2.1.2', '8.11.3.2', '8.2.1.2']`, first hit at rank 1
- citations parsed: [{'section_number': '5.2', 'section_title': 'Exclusion Criteria', 'page_start': 54, 'page_end': 56}]

```
Based on the exclusion criteria: a participant is excluded if they "had major surgery within 3 weeks prior to randomization." So the required waiting period is 3 weeks. Note: "Adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility."

SOURCES:
- §5.2 | Exclusion Criteria | p.54-56
```

### q10 — If someone had a surgical procedure recently, does the protocol bar them from joining?
*expected: answer (also acceptable: not_in_excerpts) · judge: **pass***

> The bot correctly flags that the specific surgery-exclusion information is not present in the retrieved excerpts, satisfying the "not_in_excerpts" acceptable behavior.

- retrieval: expected `['5.2']`, top-8 `['1.1', '5', '7.3', '7.1', '8.1.9.1', '10.6', '8.2.1.2', '5.2']`, first hit at rank 8
- citations parsed: [{'section_number': '5.2', 'section_title': 'Exclusion Criteria', 'page_start': 54, 'page_end': 56}]

```
The retrieved protocol excerpts do not contain information about recent surgical procedures as an exclusion criterion. The exclusion criteria chunk provided (§5.2) covers items such as investigational agent/device participation, active infection, active TB, immunodeficiency/immunosuppressive therapy, HIV, HBV/HCV — but nothing about recent surgery. This may be addressed elsewhere in the full exclusion criteria list, but it is not present in the excerpts provided.

SOURCES:
- §5.2 | Exclusion Criteria | p.54-56
```

### q11 — What prior systemic cancer therapies must a patient have already received and progressed on to be eligible for this study?
*expected: answer · judge: **pass***

> The answer accurately conveys both key facts (progression on both PD-1/L1 inhibitor and VEGF-TKI, and no more than 3 prior regimens) with correct supporting detail.

- retrieval: expected `['5.1']`, top-8 `['5.2', '5.2', '5.1', '4.1', '5.2', '8.2.1.2', '8.11.3.3', '8.11.3.2']`, first hit at rank 3
- citations parsed: [{'section_number': '5.1', 'section_title': 'Inclusion Criteria', 'page_start': 51, 'page_end': 53}]

```
Based on the inclusion criteria, a participant must have:

1. **Disease progression on or after systemic treatment for locally advanced or metastatic RCC with BOTH** a PD-1/L1 checkpoint inhibitor **and** a VEGF-TKI, given in sequence or in combination, where:
   - **PD-1/L1 checkpoint inhibitor progression** is defined by meeting ALL of:
     - Received at least 2 doses of an anti-PD-1/L1 mAb
     - Demonstrated radiographic PD during or after an anti-PD-1/L1 mAb
   - **VEGF-TKI treatment progression** is defined by:
     - Demonstrated radiographic PD during or after treatment with a VEGF-TKI

2. **Received no more than 3 prior systemic regimens** for locally advanced or metastatic RCC.

3. **For the most recently received regimen**, has demonstrated radiographic disease progression.

SOURCES:
- §5.1 | Inclusion Criteria | p.51-53
```

### q12 — How is the treatment difference in overall survival analyzed statistically?
*expected: answer · judge: **pass***

> The answer covers all four expected key facts accurately and cites the relevant section.

- retrieval: expected `['9.6.1.2']`, top-8 `['9.6.1.2', '9.6', '9.6', '9.6.1.1', '9.6.4', '9.1', '9.6.1.4', '9.5.3']`, first hit at rank 1
- citations parsed: [{'section_number': '9.6.1.2', 'section_title': 'Overall Survival', 'page_start': 96, 'page_end': 96}]

```
Per §9.6.1.2, treatment difference in overall survival (OS) is analyzed as follows:

- The nonparametric Kaplan-Meier method is used to estimate the survival curves.
- The treatment difference in survival is assessed by the stratified log-rank test.
- A stratified Cox proportional hazard model with Efron's method of tie handling is used to assess the magnitude of the treatment difference (i.e., the hazard ratio, HR).
- The HR and its 95% CI from the stratified Cox model with a single treatment covariate are reported.
- The stratification factors used for randomization (Section 6.3.2) are applied to both the stratified log-rank test and the stratified Cox model.
- Participants without documented death at the time of analysis are censored at the date the participant was last known to be alive.

Additional detail following this description is redacted in the publicly posted protocol as commercially confidential information.

SOURCES:
- §9.6.1.2 | Overall Survival | p.96-96
```

### q13 — What factors is the randomization stratified by?
*expected: answer · judge: **pass***

> The answer correctly identifies both stratification factors matching the expected key facts, with accurate additional detail.

- retrieval: expected `['6.3.2']`, top-8 `['6.3.2', '9.6.1.3', '9.6', '9.6', '9.6.1.2', '9.6.1.1', '8.1.7', '9.6']`, first hit at rank 1
- citations parsed: [{'section_number': '6.3.2', 'section_title': 'Stratification', 'page_start': 61, 'page_end': 62}]

```
Randomization is stratified by two factors (§6.3.2):

1. **IMDC prognostic scores**: 0 vs 1-2 vs 3-6
2. **Number of prior VEGF/VEGF receptor targeted therapies for advanced RCC**: 1 vs 2-3

The IMDC prognostic score is based on the following risk factors:
- **Clinical Risk Factors**: Low KPS score (<80%); Time from diagnosis to initiation of first-line treatment <1 year
- **Laboratory Risk Factors**: Low hemoglobin (<LLN); High corrected serum calcium (>ULN); High neutrophils (>ULN); High platelets (>ULN)

Prognosis categories based on number of risk factors present:
- Favorable prognosis: 0 risk factors
- Intermediate prognosis: 1-2 risk factors
- Poor prognosis: ≥3 risk factors

The most recent evaluations used to establish eligibility should be used to determine the IMDC category for stratification, and only results from central laboratory testing will be considered for the laboratory factors.

SOURCES:
- §6.3.2 | Stratification | p.61-62
```

### q14 — What should happen if a participant develops Grade 3 or Grade 4 anemia during belzutifan treatment?
*expected: answer · judge: **pass***

> The answer accurately covers all key facts—ECI reporting timelines, Grade 3 no dose modification, Grade 4 hold/reduce/discontinue rules, and mentions EPO/transfusion management.

- retrieval: expected `['10.8.3', '10.8.2', '8.4.7', '6.6.1.1']`, top-8 `['10.8.3', '6.6.1.1', '2.3', '10.8.5', '10.8.1', '2.3', '10.7.6.3', '10.8.2']`, first hit at rank 1
- citations parsed: [{'section_number': '10.8.3', 'section_title': 'Anemia Management', 'page_start': 155, 'page_end': 156}, {'section_number': '6.6.1.1', 'section_title': 'Management of Anemia', 'page_start': 68, 'page_end': 68}, {'section_number': '10.8.2', 'section_title': 'Anemia/Decreased Hemoglobin ECI Reporting', 'page_start': 155, 'page_end': 155}]

```
Based on the protocol's Belzutifan ECI Guidance (§10.8.3):

**Grade 3 anemia:**
- Dose modification is not required
- It is reported as an ECI (Event of Clinical Interest)
- While dose interruption is not required, the investigator may elect to hold belzutifan (this option applies to Grade 1-3 anemia). If belzutifan is held for anemia Grade 1-3, the participant can be re-challenged with belzutifan at the same dose.

**Grade 4 anemia** (also reported as an ECI):
- **First episode:** Hold belzutifan. Once toxicity has resolved to ≤Grade 2 or baseline, dose reduce belzutifan by 1 level.
- **Second episode:** Permanently discontinue belzutifan.

**Additional guidance applicable to both grades:**
- All attempts should be made to rule out other causes of anemia. Relevant diagnostic studies may include peripheral blood smear, reticulocyte count, LDH, haptoglobin, Coomb's test, blood levels of vitamin B12, folate, iron studies, etc.
- Management strategies noted elsewhere include EPO replacement (since decreased EPO is a potential etiology of belzutifan-induced anemia) and transfusion (§6.6.1.1, §10.8.3).

Per §10.8.2, ≥Grade 3 anemia and ≥Grade 3 decreased hemoglobin must be reported to the Sponsor as ECIs within 5 calendar days if non-serious, or within 24 hours if the event is an SAE.

SOURCES:
- §10.8.3 | Anemia Management | p.155-156
- §6.6.1.1 | Management of Anemia | p.68-68
- §10.8.2 | Anemia/Decreased Hemoglobin ECI Reporting | p.155-155
```

### q15 — What is belzutifan's current FDA approval status for renal cell carcinoma?
*expected: should_refuse_outside_knowledge · judge: **pass***

> The bot correctly declined to state any approval status and noted the excerpts don't cover regulatory approval, matching the expected refusal behavior.

- retrieval: expected `[]`, top-8 `['2.1.1', '1.1', '9.1', '2.3', '2', '2.2.6', '2.2.5.2', '2.2.6']`, **no expected section retrieved**
- citations parsed: []

```
The retrieved protocol excerpts do not contain information about belzutifan's FDA approval status for renal cell carcinoma. The chunks discuss the study rationale, preclinical/clinical data, and statistical plan, but do not address regulatory approval status.

SOURCES:
- none
```

### q16 — What overall survival benefit did this study ultimately demonstrate when its results were published?
*expected: should_refuse_outside_knowledge · judge: **pass***

> The bot refuses to report any outcome/result and correctly notes the protocol only describes planned analysis methods, without providing outside knowledge.

- retrieval: expected `[]`, top-8 `['4.2.1.4', '4.2.1.1', '10.6', '8.11.3.3', '9.6.1.2', '9.6', '2.3', '4.2']`, **no expected section retrieved**
- citations parsed: [{'section_number': '9.6.1.2', 'section_title': 'Overall Survival', 'page_start': 96, 'page_end': 96}, {'section_number': '9.6', 'section_title': 'Statistical Methods', 'page_start': 94, 'page_end': 99}]

```
The retrieved protocol excerpts do not contain that information. These excerpts describe the study's design and planned statistical methods for analyzing overall survival (e.g., Kaplan-Meier estimation, stratified log-rank test, Cox proportional hazard model), but they do not report actual trial results or outcomes. Additionally, some relevant statistical detail in §9.6/§9.6.1.2 is marked as "[REDACTED: commercially confidential information]" in the posted protocol.

SOURCES:
- §9.6.1.2 | Overall Survival | p.96-96
- §9.6 | Statistical Methods | p.94-99
```

### q17 — What specific laboratory tests make up the protocol's required safety blood panel?
*expected: not_in_excerpts · judge: **pass***

> The bot clearly flags that the Appendix 2 list is not in the excerpts and does not fabricate its contents, while providing related but clearly caveated information.

- retrieval: expected `['10.2']`, top-8 `['8.3.4', '8', '8.3', '5.1', '10.7.7', '5.2', '10.1.1', '9.6.2']`, **no expected section retrieved**
- citations parsed: [{'section_number': '8.3.4', 'section_title': 'Clinical Safety Laboratory Assessments', 'page_start': 81, 'page_end': 81}, {'section_number': '5.1', 'section_title': 'Inclusion Criteria', 'page_start': 51, 'page_end': 53}, {'section_number': '10.7.7', 'section_title': 'South Korea', 'page_start': 154, 'page_end': 154}]

```
Based on the retrieved excerpts, I cannot fully answer this. The protocol states that clinical laboratory tests to be performed are listed in "Appendix 2" (§8.3.4: "Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for the timing and frequency"), but the actual Appendix 2 content listing the specific safety blood panel tests is not included in the provided chunks.

The only laboratory-related values I have are from a country-specific inclusion criterion appendix (§10.7.7, South Korea), which lists **adequate organ function** laboratory values (not necessarily the full safety panel):
- Hematological: ANC, Platelets, Hemoglobin
- Renal: Serum creatinine or estimated CrCl (Cockcroft-Gault) or 24-hour urine testing, or GFR
- Hepatic: Total bilirubin (or direct bilirubin if total is elevated), AST (SGOT), ALT (SGPT)
- Coagulation: INR or PT, and aPTT
- Fasting serum triglycerides and total cholesterol
- Fasting glucose

This is tied specifically to Inclusion Criterion 11 (organ function adequacy) rather than being labeled as the full "safety blood panel." The retrieved excerpts do not contain the complete Appendix 2 list of clinical safety laboratory tests referenced in §8.3.4.

SOURCES:
- §8.3.4 | Clinical Safety Laboratory Assessments | p.81-81
- §5.1 | Inclusion Criteria | p.51-53
- §10.7.7 | South Korea | p.154-154
```

### q18 — Over what time period are adverse events and serious adverse events reported, relative to the last dose of study intervention?
*expected: answer · judge: **pass***

> The answer correctly states the AE and SAE reporting windows matching the expected key facts.

- retrieval: expected `['4.1']`, top-8 `['10.3.5', '10.3.5', '10.3.5', '10.3.5', '8.4.7', '4.1', '8.4.6', '6.5']`, first hit at rank 6
- citations parsed: [{'section_number': '4.1', 'section_title': 'Overall Design', 'page_start': 44, 'page_end': 45}, {'section_number': '8.4.7', 'section_title': 'Events of Clinical Interest', 'page_start': 86, 'page_end': 86}]

```
Based on the excerpts:

- **AEs**: Reported by the investigator or delegate from informed consent through **30 days following cessation of study intervention** (§4.1; §8.4.1 referenced).
- **SAEs**: Reported by the investigator or delegate from the time of intervention allocation through **90 days following cessation of study intervention**, or **30 days following cessation of study intervention if the participant initiates new anticancer therapy, whichever is earlier**.

Additionally, for Events of Clinical Interest (ECIs): those that are not SAEs are collected through 30 days following cessation of study intervention, and those that are SAEs are collected through 90 days following cessation of study intervention.

SOURCES:
- §4.1 | Overall Design | p.44-45
- §8.4.7 | Events of Clinical Interest | p.86-86
```
